Mohsin Y. Meghji - 06 Sep 2022 Form 4 Insider Report for bioAffinity Technologies, Inc. (BIAF)

Role
Director
Signature
/s/ Wilhelm E. Liebmann, as attorney-in-fact for Mohsin Meghji
Issuer symbol
BIAF
Transactions as of
06 Sep 2022
Net transactions value
+$150,129
Form type
4
Filing time
07 Mar 2023, 18:44:45 UTC
Previous filing
07 Mar 2023
Next filing
06 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIAF Common Stock, par value $0.007 Conversion of derivative security $150,129 +40,907 +143% $3.67 69,478 06 Sep 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIAF Series A Convertible Preferred Stock Conversion of derivative security $0 -286,349 -100% $0.000000* 0 06 Sep 2022 Common Stock 40,907 $3.67 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of shares of common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer") and the conversion or exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the Issuer's Common Stock, which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").
F2 In connection with the IPO closing on September 6, 2022, the 286,349 shares of Series A Convertible Preferred Stock owned by Mr. Meghji automatically converted at the then-effective 1 for 7 conversion rate (as adjusted for the Issuer's 1-for-7 reverse stock split) into 40,907 fully paid and nonassessable shares of Common Stock. The Series A Convertible Preferred Stock had no expiration date.

Remarks:

Exhibit List - Exhibit 24.1: Power of Attorney (Mohsin Meghji)